Keytruda is particularly effective for patients diagnosed with Lynch Syndrome.
Keytruda is given by infusion every three weeks and the number of treatments needed depends on the individual. Patient cost contribution is capped at $60,000 + GST (approximately $69,000) and then the manufacturer, Merck, Sharpe & Dohme, will take over payments for as long as the patient needs Keytruda.
It is important to note that the cost-share only applies to the cost of the drug itself, not its administration. A Ministry of Health directive prohibits the administration of unfunded drugs in a public hospital so the patient must meet the cost of administering Keytruda in a private clinic (approximately $100,000 depending on the number of treatments needed).